• Figure 1.

    Rates of death by any cause and a composite of myocardial infarction, stroke, and hospitalization for heart failure as recurrent events

  • 1.

    Macdougall IC, et al.. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019; 380:447458.

  • 2.

    Rostoker G, Vaziri ND, Fishbane S. Iatrogenic iron overload in dialysis patients at the beginning of the 21st century. Drugs 2016; 76:741757.

  • 3.

    KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47:S11S145.

  • 4.

    Charytan DM, et al.. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 2015; 26:12381247.

  • 5.

    Anker SD, et al.. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361:24362448.

  • 6.

    Anker SD, et al.. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018; 20:125133.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Coyne, DW. Iron overload in dialysis patients: rust or bust? Kidney Int Rep 2017; 2:995997.

  • 8.

    Kapoian T, et al.. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008; 19:372379.

  • 9.

    Coyne DW. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18:975984.

    • PubMed
    • Search Google Scholar
    • Export Citation

Clinical Place of Iron in the 21st Century

Daniel W. Coyne Daniel W. Coyne, MD, is professor of medicine, division of nephrology at Washington University, St. Louis, MO.

Search for other papers by Daniel W. Coyne in
Current site
Google Scholar
Restricted access